Clinical trials
Recurrence clinical trials
Below are recruiting recurrence clinical trials, each written for real people, not researchers. We’re tracking 1,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06994195RecruitingPhase 3
Comparing an experimental drug to standard chemo for ovarian cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT06818331RecruitingPhase 2
Electroacupuncture study for recurring brain cancer
This trial tests if a special type of electroacupuncture can help chemotherapy (paclitaxel) reach the brain more effectively in patients whose high-grade glioma has come back after surgery. The goal is to see if this combination can slow tumor growth.
China, Hangzhou City, Zhejiang ProvinceAges 18–70 - NCT06987084Enrolling by invitationEarly Phase 1
Bryophyllum Tea for Kidney Stone Prevention
This study tests whether a special tea made from the Bryophyllum pinnatum plant can help people who get calcium kidney stones. If you've had a stone or high calcium in your urine, this trial may offer a natural option to try.
Montreal, QuebecAges 18–70 - NCT06983210RecruitingPhase 2
Combination treatment for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder or urinary tract cancer that has not been treated before. The goal is to see if adding AM80 to standard chemotherapy and immunotherapy works better.
Nagoya, Aichi-kenAges 18–79 - NCT05266144Recruiting
Catheter ablation for non-valvular atrial fibrillation
This trial studies catheter ablation, a procedure that targets heart rhythm triggers, for people with atrial fibrillation (an irregular heartbeat). It may help improve rhythm control, but you must meet specific heart and testing requirements and avoid certain conditions.
Beijing, Beijing MunicipalityAges 18–80 - NCT06687382RecruitingPhase 2
MBK-01 for recurrent diverticulitis
This trial tests MBK-01, capsules made from healthy gut bacteria, to see if they can help people who keep getting diverticulitis. If you've had three or more bouts in the last three years, this study might offer a new treatment option.
Madrid, MadridAges 18–70 - NCT06982196Enrolling by invitationPhase 3
Sulodexide to prevent psoriasis return after stopping biologic
This trial tests if sulodexide, a medication that helps blood flow, can keep psoriasis from coming back after you have stopped using a biologic drug (such as strychnicolizumab) because your skin was completely clear for 6 months.
Xi'anAges 18–65 - NCT06976944RecruitingPhase 2
Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Nagoya, Aichi-kenAges 18 years+ - NCT06980025RecruitingPhase 3
Aspirin dose trial to prevent preterm birth
This study tests if a higher dose of aspirin can help prevent another early delivery in women who have had a preterm birth before. If you qualify, you would take either a standard or escalated dose of aspirin during your current pregnancy.
Birmingham, AlabamaAges 14 years+ - NCT06972901Recruiting
Preventing Crohn's recurrence after surgery using stool tests
This trial tests if checking a stool marker (fecal calprotectin) early after surgery can guide treatment with ustekinumab to prevent Crohn's disease from coming back. It's for people who had certain bowel surgery and have at least one risk factor for recurrence.
AmiensAges 18 years+ - NCT06982469Recruiting
High-dose radiation for prostate cancer return after surgery
This trial tests a high-dose radiation treatment (brachytherapy) that places tiny radioactive seeds directly into the area where your prostate was. It is for men whose prostate cancer has returned only in that area after having their prostate removed.
Pamplona, Foral Community of NavarreAges 18–80 - NCT06979609RecruitingPhase 2/Phase 3
Preventing C. diff infection with vancomycin
This trial tests whether taking vancomycin by mouth can prevent another C. diff infection when you need to take other antibiotics. It’s for patients who recently had C. diff and are about to start a new antibiotic course.
Montreal, QuebecAges 18 years+ - NCT06965114RecruitingPhase 1/Phase 2
Testing tovorafenib plus rituximab for hairy cell leukemia
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
Bethesda, MarylandAges 18 years+ - NCT06962865RecruitingPhase 2
RC108 and Furmonertinib for first-line treatment of EGFR-mutated and MET-positive NSCLC
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
BeijingAges 18–75 - NCT06970145RecruitingPhase 1/Phase 2
Anlotinib for recurrent craniopharyngioma
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
Guangzhou, GuangdongAges 18–75 - NCT06967610RecruitingPhase 2
Pirtobrutinib, venetoclax, and obinutuzumab for recurrent CLL/SLL
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
Houston, TexasAges 18 years+ - NCT06954610Recruiting
Heart Check for Stroke Risk in Atrial Fibrillation
This trial uses heart imaging to better understand stroke risk in people with atrial fibrillation (an irregular heartbeat). It may help doctors decide on the best treatment to prevent another stroke.
BernAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06952868RecruitingPhase 2
BNCT for recurrent head and neck cancer
This trial tests a special type of radiation therapy called BNCT (boron neutron capture therapy) for head and neck cancers that have come back and cannot be removed by surgery. It may be an option for patients who have already had radiation and cannot receive standard chemotherapy.
Chiayi CityAges 18–80 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
Phoenix, ArizonaAges 18 years+ - NCT06952010RecruitingPhase 1
Study of XB628 alone and with zanzalintinib for advanced solid tumors
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Rochester, MinnesotaAges 18 years+
Hear when a new Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrence?
- Yes. Clin2 currently lists 1,384 recruiting recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.